Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05101564
Title Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stanford University
Indications

Her2-receptor negative breast cancer

Therapies

Amcenestrant

Alpelisib

Infigratinib

Tamoxifen

Letrozole

Amcenestrant + Letrozole

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.